DOSE & LIFT Database
← All compounds

GHK-Cu

Animal data Peptidesrecovery Last reviewed 2026-09-24

Summary

GHK-Cu is a copper-binding tripeptide studied mainly in preclinical and cosmetic contexts for wound healing, skin remodeling, and gene-modulating effects. It has a long, safe history in topical skincare, but injectable use in humans is essentially unstudied in published trials.

Mechanism

GHK is a naturally occurring tripeptide with high affinity for copper ions, forming the GHK-Cu complex. The complex functions as a copper chaperone, delivering copper to metalloenzymes such as superoxide dismutase and lysyl oxidase, which are involved in antioxidant defense and collagen crosslinking. In cell and animal models it modulates expression of genes involved in tissue remodeling, inflammation, and oxidative stress, and it suppresses pro-inflammatory cytokines such as TNF-alpha in vitro.

Reported effects

Ratings are relative to peers in the same category, not absolute claims.

Wound healing★★★☆☆Improved healing reported across preclinical models; no controlled human data for injectable use.
Skin collagen / remodeling★★★☆☆Small human cosmetic studies suggest improved skin parameters with topical use.
Systemic regenerative effects★☆☆☆☆Gene-expression findings are real but preclinical; clinical relevance unproven.

Studied dosing — research context

Published human studies used topical formulations for skin outcomes. Injectable use in humans has not been studied in published trials, so there is no research-backed dosing to describe. This describes the state of the literature, not guidance.

Research context only. This is not a recommendation.

Safety

GHK-Cu has a long history of use in topical cosmetic formulations with a good tolerability record. Systemic (injectable) safety data in humans are essentially absent from the published literature, so the risk profile of injected use is unknown. Copper is an essential but potentially toxic metal; systemic dosing has not been characterized in trials.

Limitations

The bulk of the literature is preclinical or cosmetic, and much of it comes from a small number of research groups. There are no published randomized trials of injectable GHK-Cu for systemic outcomes in humans. Topical cosmetic effects should not be extrapolated to injected use.

References

  1. Pickart L, Vasquez-Soltero JM, Margolina A, Oxid Med Cell Longev (2012) — The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
  2. Pickart L, Margolina A, Int J Mol Sci (2018) — Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data